Revenue Growth from Winning Orders for Pharmaceutical Intermediates and Functional Chemicals
First written in FY2016-Q3. 9 of 29 entries say "Restated". Latest entry: 2026-04-10.
Kawaguchi Chemical Industry moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2023: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Worsened".
- 2026-04-10WorsenedEarnings
「Demand for dehydrating condensing agents used as pharmaceutical intermediates remained sluggish. Although sales of some products to overseas markets increased, overall sales were below the same period of the previous year.」
Although sales of some pharmaceutical intermediates to overseas markets increased, total sales fell below the same period of the previous year because of weak demand for dehydrating condensing agents. - FY2025WorsenedAnnual report
「Sales of pharmaceutical intermediates declined as demand for dehydrative condensing agents remained sluggish.」
Sales of pharmaceutical intermediates declined due to sluggish demand for dehydrative condensing agents. - FY2025-H1RestatedAnnual report
「In the intermediates segment, sales of dehydrative condensing agents for pharmaceutical intermediates declined in Japan due to sluggish demand, while overseas sales increased.」
Overseas sales of pharmaceutical intermediates increased, while lower domestic sales resulted in lower revenue for the segment as a whole. - FY2024Overseas sales up, domestic revenue down, overall revenue downAnnual report
「In pharmaceutical intermediates, overseas sales increased, but domestic sales declined, resulting in overall sales below the prior fiscal year.」
Pharmaceutical intermediates saw increased overseas sales, but overall sales fell below the prior fiscal year due to a decline in domestic sales. - FY2024-Q1WorsenedAnnual report
「For pharmaceutical intermediates, full-year sales of the dehydrative condensing agent for medical applications are expected to exceed the prior fiscal year, but sales in Q1 were below the year-earlier period.」
Full-year sales of the dehydrative condensing agent for medical applications are expected to exceed the prior fiscal year, while Q1 sales of pharmaceutical intermediates were below the year-earlier period. - FY2023AdvancedAnnual report
「In the intermediates segment, pharmaceutical intermediates focused on the production and sale of our core product, a dehydrative condensing agent for medical applications, and sales exceeded the prior fiscal year, driven mainly by domestic sales.」
For pharmaceutical intermediates, which had been expected to exceed the prior year for the full year as of Q3, full-year sales actually exceeded the prior fiscal year. - FY2023-Q3Revenue down in Q3, outlook for full-year revenue growthAnnual report
「In pharmaceutical intermediates, sales of our core product, a dehydrative condensing agent for medical applications, were concentrated in the second half of the year, and sales in Q3 were below the year-earlier period. For the full year, however, sales are expected to exceed the prior year.」
Because sales of the dehydrative condensing agent for medical applications are concentrated in the second half of the fiscal year, Q3 sales were below the year-earlier period, but full-year sales are expected to exceed the prior year. - FY2023-Q2WorsenedAnnual report
「For pharmaceutical intermediates, revenue for Japan increased, led by medical-use dehydrating condensation agents. Although sales increased for some overseas products, sales declined for others, resulting in lower total revenue than in the same period of the previous year.」
Although revenue for Japan increased, pharmaceutical intermediates as a whole fell below the same period of the previous year due to product-by-product variations in overseas markets. - FY2022-Q2RestatedAnnual report
「Pharmaceutical intermediates posted lower revenue than in the same period of the previous year for medical-use dehydrating condensation agents.」
Revenue from medical-use dehydrating condensation agents has continued to remain below the same period of the previous year. - FY2022-Q1WorsenedAnnual report
「Pharmaceutical intermediates posted lower revenue than in the same period of the previous year for medical-use dehydrating condensation agents.」
For pharmaceutical intermediates, which had increased sales in Japan and overseas markets in the previous period, revenue from medical-use dehydrating condensation agents fell below the same period of the previous year. - FY2021AdvancedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the previous period as the company focused on manufacturing and selling medical-use dehydrating condensation agents with quality and technological advantages, proactively responded to customer requirements, and increased sales in both Japan and overseas markets.」
The company increased sales in both Japan and overseas markets by focusing on medical-use dehydrating condensation agents and responding to customer requirements, resulting in full-year revenue above the previous period. - FY2021-Q3RestatedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the same period of the previous year as the company focused on manufacturing and selling medical-use dehydrating condensation agents with quality and technological advantages in both Japan and overseas markets, and proactively responded to customer requirements, increasing sales.」
Sales of pharmaceutical intermediates in Japan and overseas markets have continued to increase through the focus on medical-use dehydrating condensation agents and responses to customer requirements. - FY2021-Q2RestatedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the same period of the previous year as sales increased in both Japan and overseas markets through proactive responses to customer requirements.」
Sales in both Japan and overseas markets increased through responses to customer requirements, and revenue has continued to exceed the same period of the previous year. - FY2021-Q1RestatedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the same period of the previous year as sales increased in both Japan and overseas markets in response to customer requirements.」
Sales in both Japan and overseas markets increased through responses to customer requirements, and revenue has continued to exceed the same period of the previous year. - FY2020-Q3MitigatedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the same period of the previous year as sales of core products increased on expanding demand from pharmaceutical customers, although the failure to win orders for contract-manufactured products had an impact.」
Although the impact of not winning orders for contract-manufactured products remains, higher sales of core products driven by expanding demand from pharmaceutical customers improved revenue to above the same period of the previous year. - FY2020-Q2WorsenedAnnual report
「Pharmaceutical intermediates posted lower revenue than in the same period of the previous year because sales of core products increased on expanding customer demand, but orders for contract-manufactured products were not won.」
Although sales of core products increased, orders for contract-manufactured products were not won, causing total revenue from pharmaceutical intermediates to fall below the same period of the previous year. - FY2020-Q1WorsenedAnnual report
「Pharmaceutical intermediates posted lower revenue than in the same period of the previous year overall, although orders increased for some products and were not won for others.」
Although orders increased for some products, orders were not won for others, causing pharmaceutical intermediates as a whole to fall below the same period of the previous year. - FY2019RestatedAnnual report
「Pharmaceutical intermediates posted higher revenue than in the previous period as the company won orders in Japan, although results for overseas markets varied by product.」
Although results for overseas markets varied by product, full-year revenue exceeded the previous year due to orders won in Japan. - FY2019-Q3RestatedAnnual report
「Pharmaceutical intermediates and functional chemicals posted higher revenue than in the same period of the previous year, although overseas revenue was slightly lower, as the company won orders in Japan and increased sales.」
Orders won and higher sales in Japan offset the decline in overseas revenue, resulting in total revenue above the same period of the previous year. - FY2019-Q2RestatedAnnual report
「Pharmaceutical intermediates and functional chemicals posted higher revenue than in the same period of the previous year, although overseas revenue was slightly lower, as the company won orders in Japan.」
Orders won in Japan offset the decline in overseas revenue, resulting in total revenue above the same period of the previous year. - FY2019-Q1AdvancedAnnual report
「For pharmaceutical intermediates and functional chemicals, orders for key overseas products were received from the second quarter onward, while some products won orders in Japan during the current quarter, increasing revenue.」
Although orders for key overseas products were received from the second quarter onward, the company won orders in Japan during the current quarter and increased revenue. - FY2018WorsenedAnnual report
「Pharmaceutical intermediates and functional chemicals posted lower revenue than in the same period of the previous year overall, despite higher overseas orders, as results varied by product.」
Although overseas orders increased, total revenue fell below the same period of the previous year, deteriorating from the previous quarter's year-on-year increase. - FY2018-Q3AdvancedAnnual report
「Pharmaceutical intermediates and functional chemicals posted higher revenue than in the same period of the previous year overall, despite variations by product, partly due to an increase in overseas orders.」
Higher overseas orders drove total revenue from pharmaceutical intermediates and functional chemicals above the same period of the previous year. - FY2018-Q1AdvancedAnnual report
「Pharmaceutical intermediates and functional chemicals increased revenue for overseas markets by winning orders, but revenue for Japan fell below the same period of the previous year overall because orders for key domestic products were received from the second quarter onward.」
Although overseas markets saw new orders and higher revenue, orders for key domestic products were received from the second quarter onward, resulting in lower revenue for the segment as a whole. - FY2017-Q3AdvancedAnnual report
「Pharmaceutical intermediates and functional chemicals posted lower revenue for overseas markets due to lower customer production and competition from other companies. However, revenue in Japan increased as the company focused on expanding sales of key products and acquired new customers, resulting in total revenue above the same period of the previous year.」
Although overseas revenue declined, the company acquired new customers in Japan by expanding sales of key products, and total revenue exceeded the same period of the previous year. - FY2017-Q2AdvancedAnnual report
「Pharmaceutical intermediates and functional chemicals posted lower revenue for overseas markets due to lower customer demand and competition from other companies. However, revenue in Japan increased as the company focused on expanding sales of key products and acquired new customers, resulting in total revenue above the same period of the previous year.」
Although overseas revenue declined, the company acquired new customers by expanding sales of key products, and total revenue exceeded the same period of the previous year. - FY2017-Q1AdvancedAnnual report
「Pharmaceutical intermediates and functional chemicals posted higher revenue year on year as the company focused on expanding sales of key products and also won new orders.」
The company won new orders in addition to expanding sales of key products, resulting in higher revenue year on year. - FY2016RestatedAnnual report
「Pharmaceutical intermediates and functional chemicals posted higher revenue year on year, although results varied by product, as the company focused on winning orders for key products, resulting in higher sales.」
The explanation that the company focused on winning orders for key products and consequently increased revenue has been maintained on a full-year basis. - FY2016-Q3First statedAnnual report
「Pharmaceutical intermediates and functional chemicals posted higher revenue year on year, although results varied by product, as the company focused on winning orders for key products, resulting in higher sales.」
The initiative to focus on winning orders for key products, and the resulting increase in revenue, are described for the first time.